| scholarly article | Q13442814 |
| P50 | author | Eran Perlson | Q96738848 |
| P2093 | author name string | Francisca C Bronfman | |
| Guillermo Moya-Alvarado | |||
| Noga Gershoni-Emek | |||
| P2860 | cites work | Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease | Q21562116 |
| CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation | Q24293195 | ||
| Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis | Q24652801 | ||
| A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions | Q26781560 | ||
| Neuropathological alterations in Alzheimer disease | Q27003314 | ||
| Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics | Q27024518 | ||
| The genetics of Alzheimer disease | Q27026166 | ||
| iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease | Q27300851 | ||
| Free radicals in the physiological control of cell function | Q27860480 | ||
| Protein oxidation and degradation during postmitotic senescence. | Q40363959 | ||
| GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. | Q40470623 | ||
| Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. | Q40705160 | ||
| Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling | Q41137577 | ||
| Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-β peptide of amyloid precursor protein | Q42099415 | ||
| Glyceraldehyde-3-phosphate Dehydrogenase Aggregates Accelerate Amyloid-β Amyloidogenesis in Alzheimer Disease | Q42270108 | ||
| Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cog | Q42397173 | ||
| Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction | Q42575131 | ||
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease | Q42710153 | ||
| In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. | Q42920869 | ||
| Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using two-dimensional fluorescence difference in gel electrophoresis | Q44161341 | ||
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
| Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases | Q44727052 | ||
| Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain | Q44810166 | ||
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
| Proteome analysis of brain proteins in Alzheimer's disease: subproteomics following sequentially extracted protein preparation. | Q44939854 | ||
| Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia | Q46181670 | ||
| Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling | Q46780679 | ||
| Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. | Q46792024 | ||
| Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor | Q46832707 | ||
| Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach | Q46868947 | ||
| Redox proteomics: from protein modifications to cellular dysfunction and disease | Q46966345 | ||
| Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype | Q47866375 | ||
| Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease | Q47918430 | ||
| The ubiquitin pathway in Parkinson's disease | Q48015939 | ||
| Proteomics analysis of the Alzheimer's disease hippocampal proteome | Q48157842 | ||
| PET imaging of amyloid deposition in patients with mild cognitive impairment | Q48169392 | ||
| Phosphoproteome analysis of an early onset mouse model (TgCRND8) of Alzheimer's disease reveals temporal changes in neuronal and glia signaling pathways | Q48201617 | ||
| Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing | Q48227034 | ||
| Quantitative mass spectrometry in proteomics: a critical review | Q28238800 | ||
| S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding | Q28256078 | ||
| Trafficking and proteolytic processing of APP | Q28265871 | ||
| Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases | Q28269333 | ||
| Vesicular glycolysis provides on-board energy for fast axonal transport | Q28284720 | ||
| Aldolase directly interacts with ARNO and modulates cell morphology and acidic vesicle distribution | Q28305063 | ||
| Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers | Q28477629 | ||
| Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron | Q28589324 | ||
| Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease | Q28743561 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system | Q29617400 | ||
| Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. | Q30367032 | ||
| Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons | Q30496836 | ||
| Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice | Q30764264 | ||
| Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease | Q30789799 | ||
| Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis | Q30810502 | ||
| A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. | Q30977031 | ||
| Profiling proteins related to amyloid deposited brain of Tg2576 mice | Q31113804 | ||
| Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection | Q33204250 | ||
| Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. | Q33254291 | ||
| Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease | Q33265508 | ||
| Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples | Q33392237 | ||
| Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. | Q33431516 | ||
| Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage | Q33711010 | ||
| Alterations of brain and cerebellar proteomes linked to Aβ and tau pathology in a female triple-transgenic murine model of Alzheimer's disease. | Q33835175 | ||
| Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease | Q34002680 | ||
| The intersection of amyloid beta and tau at synapses in Alzheimer's disease | Q34054680 | ||
| Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. | Q34148953 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ | Q34281634 | ||
| SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease | Q34620335 | ||
| Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation | Q34735454 | ||
| Spatial and temporal control of Rho GTPase functions | Q34787970 | ||
| Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q34988061 | ||
| Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition | Q48269112 | ||
| Reduction in memory in passive avoidance learning, exploratory behaviour and synaptic plasticity in mice with a spontaneous deletion in the ubiquitin C-terminal hydrolase L1 gene. | Q48359758 | ||
| CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. | Q48408159 | ||
| Proteomic profiling and neurodegeneration in Alzheimer's disease. | Q48434315 | ||
| Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. | Q48476417 | ||
| Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer's disease patients. | Q48604330 | ||
| Quantitative proteomics reveals that PEA15 regulates astroglial Aβ phagocytosis in an Alzheimer's disease mouse model. | Q48613449 | ||
| Regional differences in neurotrophin availability regulate selective expression of VGF in the developing limbic cortex. | Q48707819 | ||
| Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. | Q48819507 | ||
| Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. | Q48832418 | ||
| Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. | Q48858833 | ||
| Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. | Q50762201 | ||
| Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. | Q51034709 | ||
| CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. | Q51153235 | ||
| Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. | Q51867713 | ||
| Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. | Q51891381 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. | Q52112673 | ||
| Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. | Q53256600 | ||
| Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. | Q53305742 | ||
| Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. | Q53420697 | ||
| An accurate mass tag strategy for quantitative and high-throughput proteome measurements | Q58069136 | ||
| Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process | Q60513651 | ||
| Huntington's Disease | Q80052028 | ||
| Proteomics of human cerebral microdialysate: From detection of biomarkers to clinical application | Q82775666 | ||
| Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 | Q83883527 | ||
| Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. | Q37769881 | ||
| Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity | Q37776215 | ||
| Selecting a mouse model of Alzheimer's disease | Q37802279 | ||
| Autophagy and misfolded proteins in neurodegeneration | Q37811463 | ||
| Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature | Q37982377 | ||
| Neuronal ubiquitin homeostasis | Q38107854 | ||
| Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study | Q38152257 | ||
| The critical need for defining preclinical biomarkers in Alzheimer's disease. | Q38219877 | ||
| SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes | Q38285976 | ||
| Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases | Q38289739 | ||
| Explorative and targeted neuroproteomics in Alzheimer's disease | Q38331771 | ||
| Amyloid biomarkers in Alzheimer's disease | Q38404428 | ||
| Development of quantitative-fluorescence polymerase chain reaction for the rapid prenatal diagnosis of common chromosomal aneuploidies in 1,000 samples in Singapore | Q38416373 | ||
| Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies | Q38498447 | ||
| Disruption of the nuclear p53-GAPDH complex protects against ischemia-induced neuronal damage | Q38755737 | ||
| Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age | Q38793564 | ||
| Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis | Q39756716 | ||
| Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease | Q35028860 | ||
| Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease | Q35034130 | ||
| Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects | Q35059268 | ||
| Biochemical and molecular studies using human autopsy brain tissue | Q35106821 | ||
| Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry | Q35113785 | ||
| Quantitative phosphoproteomics of Alzheimer's disease reveals cross-talk between kinases and small heat shock proteins. | Q35498406 | ||
| SWATH analysis of the synaptic proteome in Alzheimer's disease | Q35626156 | ||
| Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms | Q35763180 | ||
| Linking lipids to Alzheimer's disease: cholesterol and beyond | Q35875480 | ||
| Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. | Q35917235 | ||
| Mutations causing neurodegenerative tauopathies | Q35992153 | ||
| Glutamate receptors modulate oxidative stress in neuronal cells. A mini-review | Q36003838 | ||
| Improving (18)F-Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography Imaging in Alzheimer's Disease Studies | Q36045014 | ||
| Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment | Q36182245 | ||
| Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains | Q36243522 | ||
| Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease | Q36283394 | ||
| Genetics, transcriptomics, and proteomics of Alzheimer's disease | Q36466472 | ||
| Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. | Q36539376 | ||
| Protein biomarker discovery and validation: the long and uncertain path to clinical utility | Q36561644 | ||
| Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. | Q36568099 | ||
| Alzheimer disease: amyloidogenesis, the presenilins and animal models. | Q36701553 | ||
| Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates | Q37010140 | ||
| Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology | Q37043088 | ||
| Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease | Q37141206 | ||
| Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry | Q37146736 | ||
| Multiplicity of cerebrospinal fluid functions: New challenges in health and disease | Q37163564 | ||
| Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease | Q37180524 | ||
| Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. | Q37216153 | ||
| Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration | Q37363347 | ||
| The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. | Q37390988 | ||
| Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease | Q37442587 | ||
| Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry | Q37618631 | ||
| An update on clinical proteomics in Alzheimer's research | Q37668720 | ||
| Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives | Q37769104 | ||
| P433 | issue | 2 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neurodegeneration | Q1755122 | ||
| P304 | page(s) | 409-425 | |
| P577 | publication date | 2015-12-11 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? | |
| P478 | volume | 15 |
| Q37655619 | Correlation between receptor-interacting protein 140 expression and directed differentiation of human embryonic stem cells into neural stem cells |
| Q92199453 | Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening |
| Q101051196 | Dynamic changes in the brain protein interaction network correlates with progression of Aβ42 pathology in Drosophila |
| Q64982741 | Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease. |
| Q97652996 | Gene biomarker discovery at different stages of Alzheimer using gene co-expression network approach |
| Q37144985 | Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease |
| Q51763033 | Identification of prefrontal cortex protein alterations in Alzheimer's disease. |
| Q83229361 | Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity |
| Q52680958 | Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. |
| Q92069930 | Isoelectric point region pI≈7.4 as a treasure island of abnormal proteoforms in blood |
| Q54223105 | Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease. |
| Q49808096 | Neuroinflammation in Alzheimer's Disease: Pleiotropic Roles for Cytokines and Neuronal Pentraxins. |
| Q42548970 | Neuroproteomics: How Many Angels can be Identified in an Extract from the Head of a Pin? |
| Q64121455 | PTMiner: Localization and Quality Control of Protein Modifications Detected in an Open Search and Its Application to Comprehensive Post-translational Modification Characterization in Human Proteome |
| Q56983020 | Proteomics of neurodegenerative diseases: analysis of human post-mortem brain |
| Q47869899 | Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach |
| Q37660911 | System-based proteomic and metabonomic analysis of the Df(16)A+/- mouse identifies potential miR-185 targets and molecular pathway alterations |
| Q38368569 | The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma. |
Search more.